Clinical Trials Logo

Recurrent Esophageal Squamous Cell Carcinoma clinical trials

View clinical trials related to Recurrent Esophageal Squamous Cell Carcinoma.

Filter by:
  • None
  • Page 1

NCT ID: NCT01469598 Completed - Clinical trials for Metastatic Carcinoma

Study of Docetaxel and Gemcitabine in Metastatic Esophageal Squamous Cell Cancer

Start date: August 2011
Phase: Phase 2
Study type: Interventional

Gemcitabine is a novel analog of the nucleoside deoxycytidine that acts via inhibition of DNA synthesis.Docetaxel is a semisynthetic taxane and promotes microtubule assembly and inhibits microtubule depolymerization. In this study, patients received gemcitabine 900 mg/m2 on days 1 and 8 plus docetaxel 100 mg/m2 on day 8 with G-CSF support every 3 week.

NCT ID: NCT01178944 Completed - Clinical trials for Gastric Adenocarcinoma

Pralatrexate and Oxaliplatin in Treating Patients With Unresectable or Metastatic Esophageal, Stomach, or Gastroesophageal Junction Cancer

Start date: September 2010
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well pralatrexate and oxaliplatin work in treating patients with esophageal, stomach, or gastroesophageal junction cancer that cannot be removed by surgery or has spread from the primary site (place where it started) to other places in the body. Pralatrexate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pralatrexate with oxaliplatin may be an effective treatment for esophageal, stomach, or gastroesophageal junction cancer.